Adamas provides preliminary q4 gocovri product sales and outlines key priorities for 2020

Adamas provides preliminary fourth quarter and full year 2019 gocovri® product sales and outlines key priorities for 2020.adamas pharmaceuticals - total prescriptions of approximately 7,160 for q4 2019 and about 25,780 for full year 2019.adamas pharmaceuticals inc - expects gocovri product sales to be approximately $16.3 million for q4 2019 compared to $13.9 million for q3 2019.adamas pharmaceuticals - gocovri product sales for full year 2019 are anticipated to be about $54.6 million compared to $34.0 million for same period in 2018.
ADMS Ratings Summary
ADMS Quant Ranking